Positive Phase 2/3 trial results for Dupixent in Bullous Pemphigoid presented by Regeneron, Sanofi

From Nasdaq: 2025-03-08 21:17:51

Regeneron Pharmaceuticals Inc. and Sanofi presented positive results from a trial on Dupixent for adults with bullous pemphigoid at the 2025 AAD Annual Meeting. Patients on Dupixent had five times more disease remission at 36 weeks compared to placebo, along with reduced disease severity and itch. The trial met primary and secondary endpoints, with 20% of Dupixent patients achieving sustained disease remission compared to 4% on placebo. The FDA has accepted the application for Dupixent to treat bullous pemphigoid, with a decision expected by June 20, 2025. Additional applications are under review globally, including in the EU.



Read more at Nasdaq: Regeneron, Sanofi Present Positive Phase 2/3 Trial Results For Dupixent In Bullous Pemphigoid